Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Halogenated hydrocarbon doai
Reexamination Certificate
2004-06-25
2010-10-12
Padmanabhan, Sreeni (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Halogenated hydrocarbon doai
C514S151000, C514S183000
Reexamination Certificate
active
07812058
ABSTRACT:
The present invention provides a method for treating cancer in a mammal comprising contacting the cancer cells with a compound which is a apogossypol, derivative.
REFERENCES:
patent: 5804567 (1998-09-01), Cheng et al.
patent: 6114397 (2000-09-01), Flack et al.
patent: 6608107 (2003-08-01), Wong et al.
patent: 2003/0008924 (2003-01-01), Wang et al.
patent: 2004/0214902 (2004-10-01), Wang et al.
patent: WO-2001-72319 (2001-10-01), None
patent: WO-02/097053 (2002-12-01), None
patent: WO-2005/009434 (2005-02-01), None
Yurtcu et al. (Apoptotic effect of gossypol on human lymphocytes, Cell Biology International (2003) pp. 791-794.
Quintana et al. (Gossypol-induced DNA breaks in rat lymphocytes are secondary to cytoxicity (Toxicology Letters, vol. 117, No. 1, Sep. 30, 2000, pp. 85-94 (10).
Wang (Cytotoxic effect of gossypol on colon carcinoma cells, Life Sciences 67 (2000) 2663-2671.
“International Search Report for corresponding PCT Application No. PCT/US2004/020569”, (Apr. 1, 2005), 7 pgs.
Abou-Karam, M., “Inhibition of Oncogene Product Enzyme Activity as an Approach to Cancer Chernoprevention. Tyrosine-specific Protein Kinase Inhibition by Purpurogallin fromQuercusSp. Nutgall”,Phytotherapy Research, 13, (1999),337-340.
Becattini, B., et al., “Rational Design and Real Time, In-Cell Detection of the Proapoptotic Activity of a Novel Compound Targeting Bcl-XL”,Chemistry and Biology, vol. II, The Burnham Institute, University of California,(Mar. 19, 2004),389-395.
Degterev, A., et al., “Identification of Small-molecule Inhibitors of Interaction Between the BH3 Domain and Bcl-xL”,Nature Cell Biology3, (Feb. 2001), 173-182.
Gilbert, N. E., “Antiproliferative Activity of Gossypol and Gossypolone on Human Breast Cancer Cells”,Life Sciences, 57, 1, (1995),61-67.
Kitada, S., “Discovery, Characterization, and Structure-Activity Relationships Studies of Proapoptotic Polyphenols Targeting B-Cell Lymphocyte/Leukemia-2 Proteins”,J. Med. Chem., 46, (Sep. 25, 2003),pp. 4259-4264.
Lugovskoy, A. A., “A Novel Approach for Characterizing Protein Ligand Complexes: Molecular Basis for Specificity of Small-Molecule BcI-2 Inhibitors”,Journal of the American Chemical Society, 124, (2002),1234-1240.
Shelley, M. D., “Structure-Activity Studies on Gossypol in Tumor Cell Lines”,Anti-Cancer Drugs, 11, (2000),209-216.
Stein, R. C., “A Preliminary Clinical Study of Gossypol in Advanced Human Cancer”,Cancer Chemother. Pharmacol., 30, (1992),480-482.
Tzung, S-P. , et al., “Antimycin a Mimics a Cell-Death-Inducing BcI-2 Homology Domain 3”,Nature Cell Biology, 3, (Feb. 2001),183-191.
Van Poznak, C., “Oral Gossypol in the Treatment of Patients with Refractory Metastatic Breast Cancer: A phase I/II Clinical Trial”,Breast Cancer Research and Treatment, 66, (2001),239-248.
Wang, J-L. , et al., “Structure-Based Discovery of an Organic Compound that Binds Bcl-2 Protein and Induces Apoptosis of Tumor Cells”,Proceedings of the National Academy of Sciences of USA, 97, (Jun. 30, 2000),7124-7129.
Wu, D., “An Overview of the Clinical Pharmacology and Therapeutic Potential of Gossypol as a Male Contraceptive Agent and in Gynaecological Disease”,Drugs, 38, 3, (1989),333-341.
Zheng, T. S., “Death by Design: The Big Debut of Small Molecules”,Nature Cell Biology, 3, (2001),E1-E3.
Khafif, A. et al., “Quantitation of chemopreventive synergism between (−)-epigallocatechnin-3-gallate and curcumin in normal, premalignant and malignant human oral epithelial cells,” Carcinogenesis 19(3):419-424 (1998).
Liu, J. et al., “Inhibition of melanoma growth and metastasis by combination with (−)-epigallocatechnin-3-gallate and dacarbazine in mice,” J. Cell. Biochem. 83(4):631-642 (2001).
Suganuma, M. et al., “Synergistic effects of (−)-epigallocatechnin gallate with (−)-epicatechnin, sulindac, or tamoxifen on cancer-preventive activity in the human lung cancer cell line PC-9,” Cancer Research 59(1):44-47 (1999).
EP 93832A search report dated Jun. 6, 2008.
Pellecchia Maurizio
Reed John C.
Betton Timothy E
DLA Piper (LLP) US
Padmanabhan Sreeni
The Burnham Institute
LandOfFree
Methods and compounds useful to induce apoptosis in cancer... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compounds useful to induce apoptosis in cancer..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compounds useful to induce apoptosis in cancer... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4209954